<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23896472</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>10</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase III&#x3b2;.</ArticleTitle><Pagination><StartPage>4971</StartPage><EndPage>4981</EndPage><MedlinePgn>4971-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.01175-13</ELocationID><Abstract><AbstractText>Despite their high clinical and socioeconomic impacts, there is currently no approved antiviral therapy for the prophylaxis or treatment of enterovirus infections. Here we report on a novel inhibitor of enterovirus replication, compound 1, 2-fluoro-4-(2-methyl-8-(3-(methylsulfonyl)benzylamino)imidazo[1,2-a]pyrazin-3-yl)phenol. This compound exhibited a broad spectrum of antiviral activity, as it inhibited all tested species of enteroviruses and rhinoviruses, with 50% effective concentrations ranging between 4 and 71 nM. After a lengthy resistance selection process, coxsackievirus mutants resistant to compound 1 were isolated that carried substitutions in their 3A protein. Remarkably, the same substitutions were recently shown to provide resistance to inhibitors of phosphatidylinositol 4-kinase III&#x3b2; (PI4KIII&#x3b2;), a lipid kinase that is essential for enterovirus replication, suggesting that compound 1 may also target this host factor. Accordingly, compound 1 directly inhibited PI4KIII&#x3b2; in an in vitro kinase activity assay. Furthermore, the compound strongly reduced the PI 4-phosphate levels of the Golgi complex in cells. Rescue of coxsackievirus replication in the presence of compound 1 by a mutant PI4KIII&#x3b2; carrying a substitution in its ATP-binding pocket revealed that the compound directly binds the kinase at this site. Finally, we determined that an analogue of compound 1, 3-(3-fluoro-4-methoxyphenyl)-2-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine, is well tolerated in mice and has a dose-dependent protective activity in a coxsackievirus serotype B4-induced pancreatitis model.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Schaar</LastName><ForeName>Hilde M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Immunology, Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyssen</LastName><ForeName>Pieter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Thibaut</LastName><ForeName>Hendrik J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>de Palma</LastName><ForeName>Armando</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>van der Linden</LastName><ForeName>Lonneke</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lanke</LastName><ForeName>Kjerstin H W</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Lacroix</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Verbeken</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Conrath</LastName><ForeName>Katja</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Macleod</LastName><ForeName>Angus M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Dale R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>van de Po&#xeb;l</LastName><ForeName>Herv&#xe9;</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Neyts</LastName><ForeName>Johan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>van Kuppeveld</LastName><ForeName>Frank J M</ForeName><Initials>FJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.67</RegistryNumber><NameOfSubstance UI="D019870">1-Phosphatidylinositol 4-Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019870" MajorTopicYN="N">1-Phosphatidylinositol 4-Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23896472</ArticleId><ArticleId IdType="pmc">PMC3811463</ArticleId><ArticleId IdType="doi">10.1128/AAC.01175-13</ArticleId><ArticleId IdType="pii">AAC.01175-13</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Palacios G, Oberste MS. 2005. Enteroviruses as agents of emerging infectious diseases. J. Neurovirol. 11:424&#x2013;433</Citation><ArticleIdList><ArticleId IdType="pubmed">16287683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. 2010. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 9:1097&#x2013;1105</Citation><ArticleIdList><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawyer MH. 2002. Enterovirus infections: diagnosis and treatment. Semin. Pediatr. Infect. Dis. 13:40&#x2013;47</Citation><ArticleIdList><ArticleId IdType="pubmed">12118843</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitton JL, Cornell CT, Feuer R. 2005. Host and virus determinants of picornavirus pathogenesis and tropism. Nat. Rev. Microbiol. 3:765&#x2013;776</Citation><ArticleIdList><ArticleId IdType="pubmed">16205710</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung W-CG, Rawlinson WD, Craig ME. 2011. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ 342:d35.10.1136/bmj.d35</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d35</ArticleId><ArticleId IdType="pmc">PMC3033438</ArticleId><ArticleId IdType="pubmed">21292721</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaida A, Kubo H, Sekiguchi J, Kohdera U, Togawa M, Shiomi M, Nishigaki T, Iritani N. 2011. Enterovirus 68 in children with acute respiratory tract infections, Osaka, Japan. Emerg. Infect. Dis. 17:1494&#x2013;1497</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381549</ArticleId><ArticleId IdType="pubmed">21801632</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;v&#xea;que N, Huguet P, Norder H, Chomel J-J. 2010. Enteroviruses responsible for acute hemorrhagic conjunctivitis. Med. Mal. Infect. 40:212&#x2013;218 (In French)</Citation><ArticleIdList><ArticleId IdType="pubmed">19836177</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotbart HA. 2000. Antiviral therapy for enteroviruses and rhinoviruses. Antivir. Chem. Chemother. 11:261&#x2013;271</Citation><ArticleIdList><ArticleId IdType="pubmed">10950388</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner RB. 1998. The common cold. Pediatr. Ann. 27:790&#x2013;795</Citation><ArticleIdList><ArticleId IdType="pubmed">9866136</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Mao Q, Gao F, Wang J. 2013. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front. Med. 7:111&#x2013;121</Citation><ArticleIdList><ArticleId IdType="pubmed">23247645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F-C, Liang Z-L, Li X-L, Ge H-M, Meng F-Y, Mao Q-Y, Zhang Y-T, Hu Y-M, Zhang Z-Y, Li J-X, Gao F, Chen Q-H, Zhu Q-Y, Chu K, Wu X, Yao X, Guo H-J, Chen X-Q, Liu P, Dong Y-Y, Li F-X, Shen X-L, Wang J-Z. 2013. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 381:1037&#x2013;1045</Citation><ArticleIdList><ArticleId IdType="pubmed">23352749</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuthill TJ, Groppelli E, Hogle JM, Rowlands DJ. 2010. Picornaviruses. Curr. Top. Microbiol. Immunol. 343:43&#x2013;89</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018333</ArticleId><ArticleId IdType="pubmed">20397067</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedard KM, Semler BL. 2004. Regulation of picornavirus gene expression. Microbes Infect. 6:702&#x2013;713</Citation><ArticleIdList><ArticleId IdType="pubmed">15158778</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienz K, Egger D, Pasamontes L. 1987. Association of polioviral proteins of the P2 genomic region with the viral replication complex and virus-induced membrane synthesis as visualized by electron microscopic immunocytochemistry and autoradiography. Virology 160:220&#x2013;226</Citation><ArticleIdList><ArticleId IdType="pubmed">2820130</ArticleId></ArticleIdList></Reference><Reference><Citation>Limpens RWAL, Kumar D, Transformation T, Structures ER, Study T, Compartments D, This S, Feeds RSS, Journal ASM. 2011. The transformation of enterovirus replication structures: a three-dimensional study of single- and double-membrane compartments. mBio 2(5):e00166&#x2013;11.10.1128/mBio.00166-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00166-11</ArticleId><ArticleId IdType="pmc">PMC3187575</ArticleId><ArticleId IdType="pubmed">21972238</ArticleId></ArticleIdList></Reference><Reference><Citation>Belov GA, Nair V, Hansen BT, Hoyt FH, Fischer ER, Ehrenfeld E. 2012. Complex dynamic development of poliovirus membranous replication complexes. J. Virol. 86:302&#x2013;312</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3255921</ArticleId><ArticleId IdType="pubmed">22072780</ArticleId></ArticleIdList></Reference><Reference><Citation>Belov GA, Feng Q, Nikovics K, Jackson CL, Ehrenfeld E. 2008. A critical role of a cellular membrane traffic protein in poliovirus RNA replication. PLoS Pathog. 4(11):e1000216.10.1371/journal.ppat.1000216</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000216</ArticleId><ArticleId IdType="pmc">PMC2581890</ArticleId><ArticleId IdType="pubmed">19023417</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanke KHW, van der Schaar HM, Belov GA, Feng Q, Duijsings D, Jackson CL, Ehrenfeld E, van Kuppeveld FJM. 2009. GBF1, a guanine nucleotide exchange factor for Arf, is crucial for coxsackievirus B3 RNA replication. J. Virol. 83:11940&#x2013;11949</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772713</ArticleId><ArticleId IdType="pubmed">19740986</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels E, Duijsings D, Niu T-K, Neumann S, Oorschot VM, de Lange F, Lanke KHW, Klumperman J, Henke A, Jackson CL, Melchers WJG, van Kuppeveld FJM. 2006. A viral protein that blocks Arf1-mediated COP-I assembly by inhibiting the guanine nucleotide exchange factor GBF1. Dev. Cell 11:191&#x2013;201</Citation><ArticleIdList><ArticleId IdType="pubmed">16890159</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Schaar HM, van der Linden L, Lanke KHW, Strating JRPM, P&#xfc;rstinger G, de Vries E, de Haan C a M, Neyts J, van Kuppeveld FJM. 2012. Coxsackievirus mutants that can bypass host factor PI4KIII&#x3b2; and the need for high levels of PI4P lipids for replication. Cell Res. 22:1&#x2013;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3494396</ArticleId><ArticleId IdType="pubmed">22945356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu N-Y, Ilnytska O, Belov G, Santiana M, Chen Y-H, Takvorian PM, Pau C, van der Schaar H, Kaushik-Basu N, Balla T, Cameron CE, Ehrenfeld E, van Kuppeveld FJM, Altan-Bonnet N. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799&#x2013;811</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982146</ArticleId><ArticleId IdType="pubmed">20510927</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2011. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J. Virol. 85:2364&#x2013;2372</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067798</ArticleId><ArticleId IdType="pubmed">21177810</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibaut HJ, De Palma AM, Neyts J. 2012. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem. Pharmacol. 83:185&#x2013;192</Citation><ArticleIdList><ArticleId IdType="pubmed">21889497</ArticleId></ArticleIdList></Reference><Reference><Citation>Norder H, De Palma AM, Selisko B, Costenaro L, Papageorgiou N, Arnan C, Coutard B, Lantez V, De Lamballerie X, Baronti C, Sol&#xe0; M, Tan J, Neyts J, Canard B, Coll M, Gorbalenya AE, Hilgenfeld R. 2011. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res. 89:204&#x2013;218</Citation><ArticleIdList><ArticleId IdType="pubmed">21236302</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallay PA, Lin K. 2013. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des. Dev. Ther. 7:105&#x2013;115</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578503</ArticleId><ArticleId IdType="pubmed">23440335</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G, Vandamme A-M, Bartenschlager R, Gallay P, Lippens G, Neyts J. 2010. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One 5(10):e13687.10.1371/journal.pone.0013687</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013687</ArticleId><ArticleId IdType="pmc">PMC2965138</ArticleId><ArticleId IdType="pubmed">21060866</ArticleId></ArticleIdList></Reference><Reference><Citation>Macleod AM, Mitchell DR, Palmer NJ, Van de Poel H, Conrath K, Andrews M, Leyssen P, Neyts J. 2013. Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. ACS Med. Chem. Lett. 4:585&#x2013;589</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4030314</ArticleId><ArticleId IdType="pubmed">24900715</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Thibaut HJ, van der Linden L, Lanke K, Heggermont W, Ireland S, Andrews R, Arimilli M, Al-Tel TH, De Clercq E, van Kuppeveld F, Neyts J. 2009. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 53:1850&#x2013;1857</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2681499</ArticleId><ArticleId IdType="pubmed">19237651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels E, Duijsings D, Notebaart RA, Melchers WJG, van Kuppeveld FJM. 2005. A proline-rich region in the coxsackievirus 3A protein is required for the protein to inhibit endoplasmic reticulum-to-Golgi transport. J. Virol. 79:5163&#x2013;5173</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1069528</ArticleId><ArticleId IdType="pubmed">15795300</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Heggermont W, Leyssen P, P&#xfc;rstinger G, Wimmer E, De Clercq E, Rao A, Monforte A-M, Chimirri A, Neyts J. 2007. Anti-enterovirus activity and structure-activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[3,4-a]benzimidazoles. Biochem. Biophys. Res. Commun. 353:628&#x2013;632</Citation><ArticleIdList><ArticleId IdType="pubmed">17194441</ArticleId></ArticleIdList></Reference><Reference><Citation>Balla A, Tuymetova G, Toth B, Szentpetery Z, Zhao X, Knight ZA, Shokat K, Steinbach PJ, Balla T. 2008. Design of drug-resistant alleles of type-III phosphatidylinositol 4-kinases using mutagenesis and molecular modeling. Biochemistry 47:1599&#x2013;1607</Citation><ArticleIdList><ArticleId IdType="pubmed">18205404</ArticleId></ArticleIdList></Reference><Reference><Citation>Downing GJ, Kim S, Nakanishi S, Catt KJ, Balla T. 1996. Characterization of a soluble adrenal phosphatidylinositol 4-kinase reveals wortmannin sensitivity of type III phosphatidylinositol kinases. Biochemistry 35:3587&#x2013;3594</Citation><ArticleIdList><ArticleId IdType="pubmed">8639510</ArticleId></ArticleIdList></Reference><Reference><Citation>Godi A, Di Campli A, Konstantakopoulos A, Di Tullio G, Alessi DR, Kular GS, Daniele T, Marra P, Lucocq JM, De Matteis MA. 2004. FAPPs control Golgi-to-cell-surface membrane traffic by binding to ARF and PtdIns(4)P. Nat. Cell Biol. 6:393&#x2013;404</Citation><ArticleIdList><ArticleId IdType="pubmed">15107860</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Scott JL, Heroux A, Roy S, Lenoir M, Overduin M, Stahelin RV, Kutateladze TG. 2011. Molecular basis of phosphatidylinositol 4-phosphate and ARF1 GTPase recognition by the FAPP1 pleckstrin homology (PH) domain. J. Biol. Chem. 286:18650&#x2013;18657</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3099681</ArticleId><ArticleId IdType="pubmed">21454700</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf3;th B, Balla A, Ma H, Knight ZA, Shokat KM, Balla T. 2006. Phosphatidylinositol 4-kinase III&#x3b2; regulates the transport of ceramide between the endoplasmic reticulum and Golgi. J. Biol. Chem. 281:36369&#x2013;36377</Citation><ArticleIdList><ArticleId IdType="pubmed">17003043</ArticleId></ArticleIdList></Reference><Reference><Citation>Balla A, Tuymetova G, Tsiomenko A, Balla T. 2005. A plasma membrane pool of phosphatidylinositol 4-phosphate is generated by phosphatidylinositol 4-kinase type-III alpha: studies with the PH domains of the oxysterol binding protein and FAPP1. Mol. Biol. Cell 16:1282&#x2013;1295</Citation><ArticleIdList><ArticleId IdType="pmc">PMC551492</ArticleId><ArticleId IdType="pubmed">15635101</ArticleId></ArticleIdList></Reference><Reference><Citation>Garuti L, Roberti M, Bottegoni G. 2010. Non-ATP competitive protein kinase inhibitors. Curr. Med. Chem. 17:2804&#x2013;2821</Citation><ArticleIdList><ArticleId IdType="pubmed">20586715</ArticleId></ArticleIdList></Reference><Reference><Citation>Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JSC, Alessi DR, Cohen P. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408:297&#x2013;315</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267365</ArticleId><ArticleId IdType="pubmed">17850214</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Verbeken E, Van Aelst I, Van den Steen PE, Opdenakker G, Neyts J. 2008. Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis. Virology 382:20&#x2013;27</Citation><ArticleIdList><ArticleId IdType="pubmed">18929380</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki J, Ishikawa K, Arita M, Taniguchi K. 2012. ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication sites. EMBO J. 31:754&#x2013;766</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G. 2009. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Nat. Acad. Sci. U. S. A. 106:7577&#x2013;7582</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678598</ArticleId><ArticleId IdType="pubmed">19376974</ArticleId></ArticleIdList></Reference><Reference><Citation>Borawski J, Troke P, Puyang X, Gibaja V, Zhao S, Mickanin C, Leighton-Davies J, Wilson CJ, Myer V, Cornellataracido I, Baryza J, Tallarico J, Joberty G, Bantscheff M, Schirle M, Bouwmeester T, Mathy JE, Lin K, Compton T, Labow M, Wiedmann B, Gaither LA. 2009. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J. Virol. 83:10058&#x2013;10074</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748049</ArticleId><ArticleId IdType="pubmed">19605471</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet M-S, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, B&#xfc;hler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R. 2011. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9:32&#x2013;45</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433060</ArticleId><ArticleId IdType="pubmed">21238945</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai AW, Benita Y, Peng LF, Kim S-S, Sakamoto N, Xavier RJ, Chung RT. 2009. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 5:298&#x2013;307</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756022</ArticleId><ArticleId IdType="pubmed">19286138</ArticleId></ArticleIdList></Reference><Reference><Citation>Trotard M, Lep&#xe8;re-Douard C, R&#xe9;geard M, Piquet-Pellorce C, Lavillette D, Cosset F-L, Gripon P, Le Seyec J. 2009. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J. 23:3780&#x2013;3789</Citation><ArticleIdList><ArticleId IdType="pubmed">19608626</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaillancourt FH, Pilote L, Cartier M, Lippens J, Liuzzi M, Bethell RC, Cordingley MG, Kukolj G. 2009. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology 387:5&#x2013;10</Citation><ArticleIdList><ArticleId IdType="pubmed">19304308</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai AW, Salloum S. 2011. The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement. PLoS One 6(10):e26300.10.1371/journal.pone.0026300</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026300</ArticleId><ArticleId IdType="pmc">PMC3192179</ArticleId><ArticleId IdType="pubmed">22022594</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang N, Ma P, Lang J, Zhang Y, Deng J, Ju X, Zhang G, Jiang C. 2012. Phosphatidylinositol 4-kinase III&#x3b2; is required for severe acute respiratory syndrome coronavirus spike-mediated cell entry. J. Biol. Chem. 287:8457&#x2013;8467</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3318727</ArticleId><ArticleId IdType="pubmed">22253445</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaillancourt FH, Brault M, Pilote L, Uyttersprot N, Gaillard ET, Stoltz JH, Knight BL, Pantages L, McFarland M, Breitfelder S, Chiu TT, Mahrouche L, Faucher A-M, Cartier M, Cordingley MG, Bethell RC, Jiang H, White PW, Kukolj G. 2012. Evaluation of phosphatidylinositol-4-kinase III&#x3b1; as a hepatitis C virus drug target. J. Virol. 86:11595&#x2013;11607</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3486294</ArticleId><ArticleId IdType="pubmed">22896614</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM. 2006. A pharmacological map of the PI3-K family defines a role for p110&#x3b1; in insulin signaling. Cell 125:733&#x2013;747</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946820</ArticleId><ArticleId IdType="pubmed">16647110</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. 2008. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J. Gen. Virol. 89:2518&#x2013;2530</Citation><ArticleIdList><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillpotts RJ, Jones RW, Delong DC, Reed SE, Wallace J, Tyrrell DA. 1981. The activity of enviroxime against rhinovirus infection in man. Lancet i:1342&#x2013;1344</Citation><ArticleIdList><ArticleId IdType="pubmed">6113314</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillpotts RJ, Wallace J, Tyrrell DA, Tagart VB. 1983. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob. Agents Chemother. 23:671&#x2013;675</Citation><ArticleIdList><ArticleId IdType="pmc">PMC184785</ArticleId><ArticleId IdType="pubmed">6870216</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamarche MJ, Borawski J, Bose A, Capacci-Daniel C, Colvin R, Dennehy M, Ding J, Dobler M, Drumm J, Gaither LA, Gao J, Jiang X, Lin K, McKeever U, Puyang X, Raman P, Thohan S, Tommasi R, Wagner K, Xiong X, Zabawa T, Zhu S, Wiedmann B. 2012. Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob. Agents Chemother. 56:5149&#x2013;5156</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3457382</ArticleId><ArticleId IdType="pubmed">22825118</ArticleId></ArticleIdList></Reference><Reference><Citation>Spickler C, Lippens J, Laberge M-K, Desmeules S, Bellavance E, Garneau M, Guo T, Hucke O, Leyssen P, Neyts J, Vaillancourt FH, D&#xe9;cor A, O'Meara J, Franti M, Gauthier A. 2013. Phosphatidylinositol 4-kinase III beta is essential for the replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. Antimicrob. Agents Chemother. 57:3358&#x2013;3368</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3697394</ArticleId><ArticleId IdType="pubmed">23650168</ArticleId></ArticleIdList></Reference><Reference><Citation>Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, F&#xfc;ller C, Perner D, Zeuzem S, Sarrazin C. 2011. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J. Clin. Virol. 52:321&#x2013;327</Citation><ArticleIdList><ArticleId IdType="pubmed">21924672</ArticleId></ArticleIdList></Reference><Reference><Citation>Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C. 2009. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50:1709&#x2013;1718</Citation><ArticleIdList><ArticleId IdType="pubmed">19787809</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller R, Vignuzzi M, Andino R, Frydman J. 2007. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 21:195&#x2013;205</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1770902</ArticleId><ArticleId IdType="pubmed">17234885</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>